

Top 20: INDIA - Marginal growth

04 July 2014 | Features | By BioSpectrum Bureau

Top 20: INDIA - Marginal growth




image not found or type unknown

Country Analysis for the APAC region show that India's bioscience success story received a jolt in 2013 due to regulatory and pricing issues.

The sector grew only by 3 percent. Interestingly, India too had eight companies that crossed the \$1 billion mark. In fact, India's two leading companies Sun Pharma and Dr Reddy's have touched the \$2 billion mark for the first time.

India announced its plan to elevate its pharma industry to touch \$100 billion by 2020.

USFDA deputed training personnel to Indian state, Gujarat, to enhance quality standards of drugs exported from the state.

GE Healthcare and Cancer Treatment Services International (CTSI) plans to invest \$120 million in the country to develop 25 world-class centers across the country to improve cancer care over a period of 5 years.

INDIA: TOP 20 BIOSCIENCE COMPANIES

india-analysis

Image not found or type unknown